1 / 1

Pirtobrutinib(Jaypirca)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

TABLET

Validity period:

2 years

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

JAYPIRCA (Pirtobrutinib) is an oral kinase inhibitor specifically developed for the treatment of hematologic malignancies, such as mantle cell lymphoma. It functions by inhibiting Bruton's Tyrosine Kinase (BTK), a critical enzyme involved in the signaling pathways of B-cells, which play a key role in various B-cell malignancies, including MCL. By targeting BTK, JAYPIRCA disrupts the survival and proliferation of malignant B-cells, making it an effective option for patients with relapsed or refractory MCL.

Approved by the U.S. FDA in 2023, JAYPIRCA offers a therapeutic option for patients who have not achieved durable responses to prior lines of systemic therapy, including those who have been treated with other BTK inhibitors. This makes JAYPIRCA a valuable addition to the therapeutic armamentarium for managing challenging cases of MCL where treatment options are limited.

Generic name

Pirtobrutinib(Jaypirca)

English name

Pirtobrutinib

Alternative Names

Jaypirca

Drug prices

Indications

JAYPIRCA® is a kinase inhibitor approved for the treatment of the following conditions:

Chronic Lymphocytic Leukemia (CLL)

Small Lymphocytic Lymphoma (SLL)

Relapsed or refractory Mantle Cell Lymphoma (MCL) in adult patients who have undergone at least two lines of systemic therapy, including prior treatment with a Bruton's Tyrosine Kinase (BTK) inhibitor.

Therapeutic Target

Pirtobrutinib

Active Ingredients

oral tablet

Dosage form

TABLET

specifications

25 mg, 50 mg, and 100 mg strengths.

Description

JAYPIRCA® is an oral small-molecule kinase inhibitor that selectively targets Bruton's Tyrosine Kinase (BTK). BTK is involved in the signaling pathway of B-cells, and its inhibition helps disrupt the growth and survival of B-cell malignancies. Pirtobrutinib is designed to bind reversibly to the active site of BTK, which allows for activity in patients who have developed resistance to covalent BTK inhibitors.

Dosage and Administration

Dosage:

The recommended starting dose for JAYPIRCA® is 200 mg orally once daily.

The dose can be adjusted based on clinical response and tolerability.

Administration:

Tablets should be taken orally, with or without food.

The tablets should be swallowed whole and not crushed, split, or chewed.

Dosage Adjustments:

Dose modifications may be necessary in case of adverse effects, particularly with regard to liver function or hematological side effects.

CATEGORY NAVIGATION